J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jafron Biomedical Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Pre-Tax Income
ÂĄ852.2m
CAGR 3-Years
-12%
CAGR 5-Years
8%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Pre-Tax Income
ÂĄ596.4m
CAGR 3-Years
70%
CAGR 5-Years
91%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Pre-Tax Income
ÂĄ2B
CAGR 3-Years
5%
CAGR 5-Years
17%
CAGR 10-Years
19%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Pre-Tax Income
ÂĄ14.2B
CAGR 3-Years
19%
CAGR 5-Years
24%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Pre-Tax Income
ÂĄ884.5m
CAGR 3-Years
-27%
CAGR 5-Years
-15%
CAGR 10-Years
6%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Pre-Tax Income
ÂĄ2.1B
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
46.98 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Pre-Tax Income?
Pre-Tax Income
852.2m CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Pre-Tax Income amounts to 852.2m CNY.

What is Jafron Biomedical Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
8%

Over the last year, the Pre-Tax Income growth was 82%. The average annual Pre-Tax Income growth rates for Jafron Biomedical Co Ltd have been -12% over the past three years , 8% over the past five years .

Back to Top